| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer | Chief Executive Officer
2 companies
Mark T Iwicki is Director at PULM, with reported holdings spanning 2 companies. Mark T Iwicki's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $426K at current prices.
Our model assigns Mark T Iwicki a strong insider score of 76/100, based on 13 past trades. Over a 12-month horizon, 76.9% of those trades were profitable, with an average 12-month return of +44.3%.
Mark T Iwicki's largest disclosed position is in PULM as Director, worth about $408K. Net of sales, the PULM filings show accumulation of 307,000 shares.
Mark T Iwicki has 44 Form 4 filings on record from December 2015 to June 2026, across 5 companies: Director at Q32 Bio (QTTB), 2024–2026; Chief Executive Officer at Inhibikase Therapeutics (IKT), 2025–2026; Director at Kala Bio (KALA), 2017–2025, and 2 more.
The 73 reported transactions were 35 option or other derivative awards, 13 open-market sales, 13 dispositions back to the company and 9 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 13 sales worth about $529K.
The largest open-market sale was 154,894 shares of KALA at an average $0.81 on October 23, 2025, about $125K. Twelve months later KALA was down 100%.
None of the 7 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 2025 | KALA Kala Bio, Inc. | Director | Sell | 154,894 | $0.81 | $125,464.14 | -59.9% | -22.9% | -99.5% | |
| Jun 24, 2025 | KALA Kala Bio, Inc. | Director | Sell | 13,227 | $4.01 | $53,040.27 | -4.9% | +363.8% | -25.0% | |
| Jun 3, 2025 | KALA Kala Bio, Inc. | Director | Sell | 10,866 | $3.74 | $40,638.84 | -3.9% | +198.0% | -45.5% | |
| Jan 6, 2025 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 5,779 | $7.63 | $44,093.77 | -2.0% | -50.3% | -91.3% | |
| Jun 26, 2024 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 15,168 | $4.75 | $72,048.00 | -5.4% | +20.0% | +14.2% | |
| May 31, 2024 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 7,392 | $6.09 | $45,017.28 | -2.6% | -12.4% | -44.6% | |
| Jan 4, 2024 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 4,539 | $6.73 | $30,547.47 | -1.6% | +11.1% | +13.3% | |
| Jan 4, 2023 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 198 | $28.54 | $5,650.92 | -0.4% | -67.0% | -83.4% | |
| Oct 26, 2022 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 561 | $6.52 | $3,657.72 | -11.2% | +168.5% | +18.0% | |
| Jun 27, 2022 | KALA Kala Bio, Inc. | Chief Executive Officer | Sell | 7,975 | $0.37 | $2,950.75 | -3.1% | -37.2% | -11.6% |